Edition:
United States

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

13.30USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$13.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
56,708
52-wk High
$24.35
52-wk Low
$10.30

Select another date:

Wed, Nov 8 2017

BRIEF-Syros Pharma Q3 loss per share $0.53

* Syros reports third quarter 2017 financial results and highlights accomplishments and upcoming milestones

BRIEF-SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425

* SYROS PHARMACEUTICALS INC - PRESENTS BIOMARKER DATA FROM ITS ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 IN GENOMICALLY DEFINED AML AND MDS PATIENTS

BRIEF-Syros Pharmaceuticals says board appointed CEO Nancy Simonian as company's principal financial officer - SEC Filing

* Syros Pharmaceuticals says on Sept 28 board appointed Nancy Simonian, co's president and CEO, as company's principal financial officer - SEC Filing Source text: [http://bit.ly/2hAgfq3] Further company coverage:

BRIEF-Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​

* Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​ Source text for Eikon: Further company coverage:

BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML

* Syros receives fda orphan drug designation for SY-1425 for treatment of AML

BRIEF-Syros Pharmaceuticals Q2 loss per share $0.52

* Syros reports second quarter 2017 financial results and highlights accomplishments and upcoming milestones

BRIEF-Syros publishes foundational data supporting phase 2 clinical trial

* Syros publishes foundational data supporting ongoing phase 2 clinical trial of SY-1425 for genomically defined AML and MDS patients

BRIEF-Syros announces preclinical data on SY-1425

* Syros presents data at EHA supporting potential of SY-1425, its first-in-class selective RARα agonist, in genomically defined AML and MDS patients

Select another date: